Vaxin to hire more employees following anthrax vaccine contract

The Birmingham-based biopharmaceutical company Vaxin, Inc., recently announced plans to hire up to a dozen new staff members after being awarded a lucrative new federal contract to complete its anthrax vaccine AdVav.

The 13-year-old company cut its staff to five workers during the height of the recession, but has bounced back with the news that it has received the largest contract in its short history, according to

The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority granted the company, whose labs are located at Birmingham’s Innovation Depot, $21.7 million to finish the development of AdVav and to test its effectiveness in human subjects.

The contract will pay Vaxin $14.7 million over the next two years to determine an efficient manufacturing process for the drug. Another $7 million will be granted for the human trials, reports.

A current vaccine requires five injections over 18 months to be considered fully effective. AdVav, which is administered nasally, has shown to be effective for more than one year after a single dose in studies conducted on mice.

“This is a significant improvement over what’s available if we can continue to see those kinds of data as we move forward,” Bill Enright, Vaxin's president and CEO, said, reports.

After the contract, Vaxin could potentially make a considerable amount of money from the new vaccine if it produces it for public health stockpiles, the military and first responders.